170 related articles for article (PubMed ID: 8843954)
1. Serum tumor markers in chronic liver disease.
Kadayifci A; Simsek H; Savas MC; Toppare M
Neoplasma; 1996; 43(1):17-21. PubMed ID: 8843954
[TBL] [Abstract][Full Text] [Related]
2. The use of tissue polypeptide specific antigen as a marker in liver diseases.
Cetin T; Oğuz A; Algan P; Yildirim IS
Turk J Gastroenterol; 2003 Sep; 14(3):177-80. PubMed ID: 14655061
[TBL] [Abstract][Full Text] [Related]
3. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis, and its relationship with circulating thrombocyte counts.
Koruk M; Onuk MD; Akçay F; Savas MC
Hepatogastroenterology; 2002; 49(48):1645-8. PubMed ID: 12397754
[TBL] [Abstract][Full Text] [Related]
4. [Occurrence of increased alpha-fetoprotein in non-neoplastic hepatopathies of alcoholic or non-alcoholic origin].
Pol S; Nalpas B; Bezeaud A; Bréchot C; Berthelot P
Gastroenterol Clin Biol; 1986 Feb; 10(2):112-6. PubMed ID: 2422087
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of CA 50 in nonmalignant liver diseases: a clinical and biochemical study.
Collazos J; Genolla J; Ruibal A
Am J Gastroenterol; 1993 Mar; 88(3):409-12. PubMed ID: 8438849
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
7. The importance of serum and ascites fluid alpha-fetoprotein, carcinoembryonic antigen, CA 19-9, and CA 15-3 levels in differential diagnosis of ascites etiology.
Sari R; Yildirim B; Sevinc A; Bahceci F; Hilmioglu F
Hepatogastroenterology; 2001; 48(42):1616-21. PubMed ID: 11813585
[TBL] [Abstract][Full Text] [Related]
8. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
9. Measurement of tumor markers in chronic hemodialysis patients.
Tzitzikos G; Saridi M; Filippopoulou T; Makri A; Goulioti A; Stavropoulos T; Stamatiou K
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):50-3. PubMed ID: 20061692
[TBL] [Abstract][Full Text] [Related]
10. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis.
Cicognani C; Malavolti M; Morselli-Labate AM; Zamboni L; Sama C; Barbara L
Arch Intern Med; 1997 Apr; 157(7):792-6. PubMed ID: 9125012
[TBL] [Abstract][Full Text] [Related]
11. [Decrease of haptoglobin serum level in patients with chronic viral hepatitis C].
Bacq Y; Schillio Y; Brechot JF; De Muret A; Dubois F; Metman EH
Gastroenterol Clin Biol; 1993; 17(5):364-9. PubMed ID: 8349072
[TBL] [Abstract][Full Text] [Related]
12. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.
Marrero JA; Su GL; Wei W; Emick D; Conjeevaram HS; Fontana RJ; Lok AS
Hepatology; 2003 May; 37(5):1114-21. PubMed ID: 12717392
[TBL] [Abstract][Full Text] [Related]
13. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Watanabe K; Magario N; Yokoo T; Naraki T
Cancer; 1999 Feb; 85(4):812-8. PubMed ID: 10091758
[TBL] [Abstract][Full Text] [Related]
14. Abnormal serum tumour markers values do not imply the presence of extra-hepatic malignancies in patients with chronic liver disease.
Puoti C; Bellis L; Guarisco R
Dig Liver Dis; 2010 May; 42(5):387. PubMed ID: 19181575
[No Abstract] [Full Text] [Related]
15. [Quantitative analysis of serum hyaluronic acid and its application in liver disease].
Qiang Y; Wang J; Sun W
Zhonghua Yu Fang Yi Xue Za Zhi; 1995 Jan; 29(1):21-3. PubMed ID: 7600884
[TBL] [Abstract][Full Text] [Related]
16. Influence of cardiopulmonary resuscitation on levels of tumour markers.
Berent R; Auer J; Porodko M; Lamm G; Weber T; Wimmer E; Seier J; Aspöck G; Eber B
Eur J Cancer Care (Engl); 2006 Jul; 15(3):252-6. PubMed ID: 16882121
[TBL] [Abstract][Full Text] [Related]
17. Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma.
Beneduce L; Castaldi F; Marino M; Quarta S; Ruvoletto M; Benvegnù L; Calabrese F; Gatta A; Pontisso P; Fassina G
Cancer; 2005 Jun; 103(12):2558-65. PubMed ID: 15887222
[TBL] [Abstract][Full Text] [Related]
18. [Clinico-diagnostic significance of the determination of bile acids in chronic liver diseases].
Andreuzzi B; Vai C; Santese R; Andreuzzi P; Cantoni L
Minerva Med; 1984 Mar; 75(13):749-56. PubMed ID: 6717831
[TBL] [Abstract][Full Text] [Related]
19. [A quantitative study of the relationship between levels of liver fibrosis markers in sera and fibrosis stages of liver tissues of patients with chronic hepatic diseases].
Ding XJ; Li SB; Li SZ; Liu HS; Liu B; Xu FM; Gu RW
Zhonghua Gan Zang Bing Za Zhi; 2005 Dec; 13(12):911-4. PubMed ID: 16381637
[TBL] [Abstract][Full Text] [Related]
20. Serum xanthine oxidase in human liver disease.
Battelli MG; Musiani S; Valgimigli M; Gramantieri L; Tomassoni F; Bolondi L; Stirpe F
Am J Gastroenterol; 2001 Apr; 96(4):1194-9. PubMed ID: 11316169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
